Comments
Suven Life Sciences on Wednesday informed the bourses of the grant of one product patent each from Israel, Japan, New Zealand and Sri Lanka. The patent is for new chemical entities indicated for the treatment of disorders associated with neurodegenerative diseases such as Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, pain, Parkinson’s disease, and Schizophrenia, among others. Shareholders will closely monitor further developments.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.